key: cord-0911382-mrgw2mnx
authors: Si, Longlong; Bai, Haiqing; Rodas, Melissa; Cao, Wuji; Oh, Crystal Yuri; Jiang, Amanda; Moller, Rasmus; Hoagland, Daisy; Oishi, Kohei; Horiuchi, Shu; Uhl, Skyler; Blanco-Melo, Daniel; Albrecht, Randy A.; Liu, Wen-Chun; Jordan, Tristan; Nilsson-Payant, Benjamin E.; Logue, James; Haupt, Robert; McGrath, Marisa; Weston, Stuart; Nurani, Atiq; Kim, Seong Min; Zhu, Danni Y.; Benam, Kambez H.; Goyal, Girija; Gilpin, Sarah E.; Prantil-Baun, Rachelle; Powers, Rani K.; Carlson, Kenneth; Frieman, Matthew; tenOever, Benjamin R.; Ingber, Donald E.
title: Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics
date: 2020-08-19
journal: bioRxiv
DOI: 10.1101/2020.04.13.039917
sha: 5a3396c6e07a333da848102ff21155472a64347d
doc_id: 911382
cord_uid: mrgw2mnx

The rising threat of pandemic viruses, such as SARS-CoV-2, requires development of new preclinical discovery platforms that can more rapidly identify therapeutics that are active in vitro and also translate in vivo. Here we show that human organ-on-a-chip (Organ Chip) microfluidic culture devices lined by highly differentiated human primary lung airway epithelium and endothelium can be used to model virus entry, replication, strain-dependent virulence, host cytokine production, and recruitment of circulating immune cells in response to infection by respiratory viruses with great pandemic potential. We provide a first demonstration of drug repurposing by using oseltamivir in influenza A virus-infected organ chip cultures and show that co-administration of the approved anticoagulant drug, nafamostat, can double oseltamivir’s therapeutic time window. With the emergence of the COVID-19 pandemic, the Airway Chips were used to assess the inhibitory activities of approved drugs that showed inhibition in traditional cell culture assays only to find that most failed when tested in the Organ Chip platform. When administered in human Airway Chips under flow at a clinically relevant dose, one drug – amodiaquine - significantly inhibited infection by a pseudotyped SARS-CoV-2 virus. Proof of concept was provided by showing that amodiaquine and its active metabolite (desethylamodiaquine) also significantly reduce viral load in both direct infection and animal-to-animal transmission models of native SARS-CoV-2 infection in hamsters. These data highlight the value of Organ Chip technology as a more stringent and physiologically relevant platform for drug repurposing, and suggest that amodiaquine should be considered for future clinical testing.

Chips 108

To initially assess whether Organ Chip technology 5-8 can be used to create a 109 preclinical in vitro model for therapeutics discovery, we tested it against a drug that is 110 used clinically for treatment of influenza A viral infections. The human Lung Airway Chip 111 is a microfluidic device that contains two parallel microchannels separated by an 112 extracellular matrix (ECM)-coated porous membrane (Fig. 1a) 16 . Primary human lung 113 airway basal stem cells are grown under an air-liquid interface (ALI) on one side of the 114 membrane in the 'airway channel', while interfaced with a primary human lung 115 endothelium grown on the opposite side of the same membrane, which is exposed to 116 continuous fluid flow of culture medium within the parallel 'vascular channel' (Fig. 1a) . 117

This device supports differentiation of the lung airway basal stem cells into a 118 mucociliary, pseudostratified epithelium with proportions of airway-specific cell types 119 (ciliated cells, mucus-producing goblet cells, club cells, and basal cells) (Extended Data 120 Fig. 1a) , as well as establishment of continuous ZO1-containing tight junctions and cilia 121 ( Fig. 1b) , permeability barrier properties, and mucus production (Extended Data Fig.  122 1b,c) similar to those observed in human airway in vivo 17 , as well as in prior Airway 123

Chip studies that used a membrane with smaller pores that did not permit immune cell 124 transmigration 16 . The underlying human pulmonary microvascular endothelium also 125 endothelium and the ECM-coated pores of the intervening membrane, and up into the 172 airway epithelium over hours (Fig. 2b bottom) . The neutrophils targeted the influenza A 173 virus nucleoprotein (NP)-positive infected airway cells (Extended Data Fig. 3) and 174 induced them to coalesce into clusters that decreased in size over time, resulting in 175 clearance of the virus, as evidenced by the disappearance of GFP-positive cells over a 176 period of 1-2 days (Fig. 2b bottom) . Consistent with the ability of H3N2 virus to induce 177 stronger inflammation relative to H1N1 in vivo 21 , H3N2 also stimulated more neutrophil 178 recruitment than H1N1 (Fig. 2c) , and neutrophil infiltration into the epithelium 179 significantly decreased the viral titers of both H1N1 and H3N2 on-chip (Fig. 2d) , 180 consistent with the protective role that neutrophils provide by clearing virus in vivo 22 . 181 H1N1 infection also was accompanied by increased secretion of various inflammatory 182 cytokines and chemokines, including IL-6, IP-10, RANTES, interferon-β, and MCP-1, 183 which could easily be measured in the effluent from the vascular channel (Fig. 2e) . were infected with H3N2 and H5N1 viruses that are known to produce more severe 191 clinical symptoms than H1N1 in patients, we found that they also stimulated production 192 of higher levels of cytokines and chemokines, and the most virulent H5N1 strain 193 that patients infected with H5N1 have increased serum concentrations of these 195 inflammatory factors relative to those with H1N1 or H3N2, which significantly contributes 196 to disease pathogenesis 21 . 197

To explore whether the Airway Chip can be used to evaluate the efficacy of 199 potential antiviral therapeutics, we first tested oseltamivir (Tamiflu), which is the anti-200 influenza drug most widely used in the clinic. As oseltamivir is metabolized by the liver 201 to release oseltamivir acid in vivo, we introduced this active metabolite into the vascular 202 channel of Airway Chip infected with H1N1 virus, mimicking its blood levels after oral 203 administration. Oseltamivir (1 µM) efficiently inhibited influenza A virus replication (Fig.  204   3a) , prevented virus-induced compromise of barrier function (Fig. 3b) and disruption of 205 epithelial tight junctions (Fig. 3c) , and decreased production of multiple cytokines and 206 chemokines on-chip (Fig. 3d) . Importantly, similar anti-influenza efficacy was detected 207 in a randomized controlled trial where treatment with Oseltamivir also led to one log 208 drop in viral titers in nasopharyngeal samples provided by 350 patients 23 . Thus, the 209 Airway Chip faithfully replicates the effects of oseltamivir previously observed in 210 humans, suggesting that it may serve as a useful preclinical model to evaluate potential 211 therapies for virus-induced human lung infections in a preclinical setting. 212

Given that host serine proteases on human airway epithelial cells play critical 214 roles in influenza A virus propagation 12,24 , and their expression is significantly elevated 215 by delivering them into the airway channel of influenza virus-infected chips (e.g, to 218 mimic intratracheal delivery by aerosol, nebulizer, or inhaler). These studies revealed 219 that two clinically used anticoagulant drugs, nafamostat (Fig. 3e) and trasylol 220 (Extended Data Fig. 4a) , significantly reduced influenza H1N1 and H3N2 titers on-chip. 221

Further exploration of nafamostat's actions revealed that it protects airway barrier 222 function (Extended Data Fig. 4b ) and tight junction integrity (Extended Data Fig. 4c) , 223 and decreases production of cytokines and chemokines (Extended Data Fig. 4d) . 224

Nafamostat and the other protease inhibitors appeared to act by efficiently blocking the 225 serine proteases-TMPRSS11D and TMPRSS2-mediated enzymatic cleavage of 226 influenza A viral HA0 protein into HA1 and HA2 subunits (Extended Data Fig. 4e) , 227 which is required for viral entry 25 . 228

When we added nafamostat or oseltamivir at different time points during influenza 229 virus infection on-chip, both nafamostat and oseltamivir exhibited prophylactic and 230 therapeutic effects (Fig. 3f) . However, oseltamivir only produced therapeutic effects 231 when was administered within 48 h post-infection (Fig. 3f) . This is consistent with the 232 observation that oseltamivir is only recommended for clinical use within 2 days of 233 influenza virus infection 26 , which is one of the important limitations of using this antiviral 234 therapeutic clinically. Nafamostat also exhibited its inhibitory effects over a 48 h time 235 period (Fig. 3f) . Impressively, however, combined administration of nafamostat and 236 oseltamivir exerted more potent inhibition of influenza virus infection, and this combined 237 regimen was able to double oseltamivir's treatment time window from 48 to 96 hours 238 (Fig. 3f) . 239

Given the faithful recapitulation of human lung responses to influenza infection, 241

we quickly pivoted our effort to focus on SARS-CoV-2 infection when we learned of the 242 emerging COVID-19 pandemic. To alleviate safety concerns and immediately initiate 243 work in a BSL2 laboratory, we designed SARS-CoV-2 pseudoparticles (SARS-CoV-244 2pp) that contain the SARS-CoV-2 spike (S) protein assembled onto luciferase reporter 245 gene-carrying retroviral core particles 27 , based on the genome sequence of SARS-CoV-246 2 released in GenBank on January 12, 2020 28 . We confirmed the incorporation of Fig. 5b) . These pseudotyped S protein-expressing viral particles 253 faithfully reflect key aspects of native SARS-CoV-2 entry into host cells via binding to its 254 ACE2 receptor 30 , and thus, they can be used to test potential entry inhibitors of SARS-255

CoV-2 18,27 . Vesicular stomatitis virus (VSV) GP protein pseudoparticles (VSVpp) were 256 also generated and used in parallel studies to exclude toxic and non-specific effects of 257 SARS-CoV-2 entry inhibitors 18,27 . 258

We then used the Huh-7 cells in a 96-well plate assay format to test the effects of 259 multiple drugs on SARS-CoV-2pp entry that have been approved by the FDA for other 260 medical indications, including chloroquine, hydroxychloroquine, amodiaquine, 261 toremifene, clomiphene, arbidol, verapamil, and amiodarone. These drugs were chosen 262 they have been shown to inhibit infection by other SARS, influenza, and Ebola viruses 31-264 33 . All of these drugs demonstrated dose-dependent inhibition of SARS-CoV-2pp entry 265 in Huh-7 cells without producing any detectable cell toxicity (Extended Data Fig. 6 ) 266 when added at 1 and 5 µM simultaneously with the virus and culturing for 72 hours (Fig.  267   4a) . These results were promising; however, Huh-7 cells only express low levels of 268 ACE2 34 and they do not express TMPRSS2 29,35 . In addition, this cell line was derived 269 from a human liver tumor, whereas SARS-CoV-2 preferentially targets lung in humans. with our finding that these highly differentiated lung cells express high levels of its ACE2 284 receptor as well as TMPRSS2 (Fig. 1c-e) , which mediate cellular entry of native SARS-285 the SARS-CoV-2pp preferentially infected ciliated cells in the human Lung Airway Chip 287 (Extended Data Fig. 7c) , as native SARS-CoV-2 virus does in vivo 19 . 288

Next, we pretreated the human Airway Chips by perfusing their vascular channel 289 for 24 hours with amodiaquine, toremifene, clomiphene, chloroquine, 290 hydroxychloroquine, arbidol, verapamil, or amiodarone at clinically relevant levels 291 similar to their maximum concentration (Cmax) in blood reported in humans ( Table 1) mRNA revealed that only three of these drugs  amodiaquine, toremiphene, and 296 clomiphene  significantly reduced viral entry (by 59.1%, 51.1% and 28.1%, 297 respectively) (Fig. 4b) without producing detectable cytotoxicity (Extended Data Fig.  298 6b) under these more clinically relevant experimental conditions. Importantly, 299 hydroxychloroquine, chloroquine, and arbidol that have no effect on SARS-CoV-2pp 300 entry in our human Airway Chips also failed to demonstrate clinical benefits in human 301 clinical trials 1,2,36 . When administered to patients, the most potent drug amodiaquine is 302 rapidly transformed (half life ~ 5 hr) into its active metabolite, desethylamodiaquine, 303 which has a much longer half-life (~ 9-18 days) 37 . When desethylamodiaquine was 304 administered at a clinically relevant dose (1 µM; Table 1) in the human Airway Chips, it 305 also reduced entry of the pseudotyped SARS-CoV-2 viral particles by ~60% (Extended expressing human lung A549 cells infected with native SARS-CoV-2 when administered 320 at 10 µM (Fig. 5b) . 321

Given this potent inhibitory activity against native SARS-CoV-2, we then 322 evaluated amodiaquine in a hamster COVID-19 model in which the animals are infected 323 intranasally with SARS-CoV-2 virus (10 3 PFU). The animals were treated once a day for 324 4 days with amodiaquine (50 mg/kg via subcutaneous injection) beginning one day prior 325 to SARS-CoV-2 infection. The dosing regimen was selected based on a PK study for 326 amodiaquine that was carried out in healthy hamsters in parallel. A single dose of 327 amodiaquine (50 mg/kg) injected subcutaneously revealed that the Cmax for 328 amodiaquine and its active metabolite desethylamodiaquine were ~ 3.2 and 0.7 µM, 329 respectively; while the T1/2 for amodiaquine was 18.1 hours, that of its active metabolite Importantly, amodiaquine treatment of infected hamsters resulted in ~70% 341 reduction in SARS-CoV-2 viral load measured by RT-qPCR of the viral N transcript 342 when measured 3 days after the viral challenge (Fig. 5c) . Immunohistochemical 343 analysis of lungs from these animals confirmed that amodiaquine treatment resulted in a 344 significant reduction in expression of SARS-CoV-2 N protein in these tissues (Fig. 5d) . 345

We then carried out studies using a SARS-CoV-2 transmission model in which vehicle 346 or amodiaquine-treated healthy animals are placed in the same cage with animals that 347 had been infected with SARS-CoV-2 virus one day earlier. In vehicle controls, this 348 experimental setup results in a 100% transmission within two days of exposure. In 349 contrast, the same amodiaquine treatment regimen as described above resulted in a 350 90% inhibition of SARS-CoV-2 infection as measured by quantifying N transcript levels 351 (Fig. 5e) . These results were further corroborated in an independent experiment where 352 amodiaquine-treated animals showed a greater than one log decrease in viral titers 353 measured by plaque assays when compared to vehicle (Fig. 5f) . To our knowledge, this together, these results confirm that the antiviral activities identified in the human Lung 356

Airway Chips translate to the in vivo setting, and suggest that amodiaquine may provide 357 significant protection when taken prophylactically. 358 359

Taken together, these data show that human Organ Chips, such as the Lung 361

Airway Chip, can be used to rapidly identify existing approved drugs that may be 362 repurposed for pandemic virus applications in crisis situations that require accelerated 363 development of potential therapeutic and prophylactic interventions. Our work on 364

repurposing of therapeutics for COVID-19 was initiated on January 13, 2020 (1 day after 365 the sequence of viral genome was published in GenBank 28 ), and our first results with 366 drugs in Airway Chips were obtained three weeks later. The ability to apply drugs using 367 dynamic fluid flow on-chip enables the human lung cells to be treated with more 368 clinically relevant dynamic drug exposures on-chip. While drugs were administered at 369 levels similar to their Cmax here to compare relative potencies, one caveat is that we did 370 not quantify drug absorption or protein binding in this study. Importantly, by carrying out 371 mass spectrometry measurements of drug levels in these devices, full PK profiles can 372 be recapitulated in these Organ Chip models 8 , which should further aid clinical 373 translation in the future. While animal models remain the benchmark for validation of 374 therapeutics to move to humans, it is important to note that human Organ Chips are 375 now being explored as viable alternatives to animal models 38 and regulatory agencies 376 are encouraging pharmaceutical and biotechnology companies to make use of data 377 Given the alarming rate at which the SARS-CoV-2 pandemic is spreading, 415 clinicians must seriously consider the relative risks and benefits of using any existing 416 approved drug as a new COVID-19 therapy with specific patient populations (e.g., male 417 versus female, young versus old, Caucasian versus African, etc.) before initiating any 418 trial in their local communities. Our findings raise the possibility that amodiaquine could 419 be explored as a chemoprophylaxis therapy to prevent spread of COVID-19 and help 420 people return to their workplace by treating healthy patients for 3 days, which could then 421 offer protection for an additional 2 weeks. If amodiaquine were to be advanced to clinical trials for prevention of COVID-19, it would be critical to select patient populations 423 carefully and appropriate clinical assessments (e.g., blood and liver function tests) 424

should be carried out before and during administration of drug. This prophylactic 425 therapy may be particularly valuable in Africa and other low resource nations where this 426 inexpensive drug is more readily available and where more expensive alternative 427 therapies are not feasible. 428

The current COVID-19 pandemic and potential future ones caused by influenza 429 viruses or other coronaviruses, represent imminent dangers and major ongoing public 430 health concerns. When it comes to repurposing existing antiviral agents, every 431 experimental assay has its limitations. However, our results suggest that combining 432 (RBD) fragment from the S1 region was used as a control (BEI resources, NR-52306). 615

Similar results were also obtained using a commercially available pseudotyped SARS-616

CoV-2 S protein expressing viral particles (Amsbio LLC). BioTek Synergy HTX plate reader (BioTek Instruments Inc., Winooski, VT) using the 667 Gen5 software (v7.07, Biotek Instruments Inc., Winooski, VT). Similar results were 668 obtained with wild type SARS-CoV-2 virus, using a previously published method 45 . 669

Hamster PK studies. Amodiaquine dihydrochloride dihydrate (Sigma, #A2799) was 670 formulated at 10 mg/ml in 12% sulfobutylether-β-cyclodextrin in water at pH 5.0 and 671 administered to LVG male hamsters (n=3) at 50 mg/kg by subcutaneous injection (dose 672 volume of 5 ml/kg). Blood samples were drawn at 0.5, 1, 2, 4, 8 and 24 hours and 673 plasma was prepared. At 24 hours, animals were anesthetized and then perfused to homogenized in 1 mL of PBS, and homogenates were then spun down at 10,000 rcf for 711 5 minutes; the supernatant was subsequently discarded, and the lung pellet was 712 resuspended in Trizol. The same protocol was used in our animal-to-animal infection 713 model, except amodiaquine was administered to healthy hamsters for one day before 714 they were housed with untreated hamsters that were infected with SARS-CoV-2 one 715 day earlier, and drug continued to be administered daily for 3 more days, after which 716 infection transmission was quantified. 717 for 2 more days. The epithelium from the chips were collected for detection of viral pol 985 gene by qRT-PCR; viral entry in untreated chips was set as 100%. *, P < 0.05; **, P < 986 0.01; ***, P < 0.001. 987 

A Randomized Trial of Hydroxychloroquine as

Postexposure Prophylaxis for Covid-19

Effect of High vs Low Doses of Chloroquine Diphosphate 780 as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory 781

Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

Insights from nanomedicine into chloroquine 784 efficacy against COVID-19

Emerging preclinical evidence does not support broad use of

Hydroxychloroquine in COVID-19 patients

A human disease model of drug toxicity-induced pulmonary edema 792 in a lung-on-a-chip microdevice

On-chip recapitulation of clinical bone marrow toxicities and 795 patient-specific pathophysiology

Quantitative prediction of human pharmacokinetic responses to 798 drugs via fluidically coupled vascularized organ chips

Physiologically Based Pharmacokinetic and 801

Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips

Tropism, replication competence, and innate immune 805 responses of influenza virus: an analysis of human airway organoids and ex-vivo 806 bronchus cultures

Human organoid cultures: 809 transformative new tools for human virus studies

Induction of proinflammatory cytokines in human 838 macrophages by influenza A (H5N1) viruses: a mechanism for the unusual 839 severity of human disease?

Neutrophil extracellular traps in immunity and disease

Efficacy and safety of oseltamivir in treatment of acute 843 influenza: a randomised controlled trial

Differentiated human airway organoids to assess infectivity of 847 emerging influenza virus

Airway proteases: an emerging drug target for 850 influenza and other respiratory virus infections

Influenza treatment with antiviral medications

Triterpenoids manipulate a broad range of virus-host fusion via 855 wrapping the HR2 domain prevalent in viral envelopes

alone and in combination in healthy volunteers

Is it time for reviewer 3 to request human organ chip experiments 886 instead of animal validation studies? Advanced Science

Biology-inspired microphysiological systems to advance patient 888 benefit and animal welfare in drug development

Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients 891 with mild/moderate COVID-19: an exploratory randomized controlled trial

Identification of antiviral drug candidates against SARS-CoV-2 894 from FDA-approved drugs

FDA approved 897 drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 <em>in vitro</em>

Pharmacokinetics and pharmacodynamics of a new ACT 902 formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration Ebola Virus Disease

International Notes Agranulocytosis Associated with the Use of

Amodiaquine for Malaria Prophylaxis

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection 911

Gradient in the Respiratory Tract

Imbalanced Host Response to SARS-CoV-2 Drives 914 Development of COVID-19

3 PFU) as measured by qPCR 995 for subgenomic RNA encoding SARS-CoV-2 N protein. **, p< 0.01. (d) Hematoxylin-996 and SARS-CoV-2 N-stained histological sections of lungs from animals that were mock 997 treated

Reduction 999 of viral load in the lungs of hamsters treated once a day for 4 days with amodiaquine 1000 (50 mg/kg) beginning 1 day prior to co-caging with SARS-CoV-2 infected animals as 1001 measured by qPCR for RNA encoding SARS-CoV-2 N protein. *, p< 0.05. (f) Graph 1002 depicting plaque forming units (PFU) per mL of lung homogenate from hamsters 1003 pretreated with vehicle or amodiaquine one day prior to being exposed to infected 1004 animals

Extended Data Fig. 1. Characterization of human Airway Chip. (a) Comparison 1011 of the percentage of different lung epithelial cell types in the human Airway Chip 1012 presented here compared with those found in living human airway and in our previously 1013 published Airway Chip created using a membrane

permeability (log Papp) of the human Airway Chip assessed using Cascade blue

Da) as fluorescent tracer at 1 to 4 weeks of differentiation under an ALI compared with 1016 chips without cells (Empty). (c) Mucus production at week 1, 2, 3, and 4 post-Extended Data Fig. 2. (a) Comparison of infectivity and replication of GFP-labeled

PR8 (H1N1) in the differentiated epithelium of human lung Airway chip, undifferentiated 1025 airway epithelium on-chip, and human vascular endothelium on-chip. Graph showing 1026 replication kinetics of influenza PR8 (H1N1) virus (MOI = 0.001) in differentiated these respective chips at 48 h post-infection

DAPI-stained nuclei). (b) Immunofluorescence micrographs showing apical cilia 24

MOI = 0.1) compared to untreated 1033 chips (Ctrl). (c) Characterization of the replication competence of influenza virus in 1034 human lung Airway Chips created with lung airway epithelial basal stem cells obtained 1035 from 5 different healthy donors. Influenza PR8 (H1N1) virus was used to

Extended Data Fig. 3. Higher magnification immunofluorescence micrographs 1042 showing specific binding of neutrophils (white) to cells infected by WSN (H1N1) or

HK/68 (H3N2), which are stained for viral NP (green) (bar, 50 µm)

Virus titer 1049 detection showing the effects of Trasylol (aprotinin) on virus replication of H1N1 and 1050 H3N2 in Airway chips 48 h post-infection (Trasylol, gray bars) compared to untreated 1051 chips (Ctrl, white bars). (b) Barrier permeability (log Papp) within human Airway Chips 1052 measured 48 h post-infection with H1N1 (MOI = 0.1) (+ Virus) in the presence (+) or 1053 absence (-) of 10 µM Nafamostat

Immunofluorescence micrographs showing preservation of ZO1-containing tight 1055 junctions seen that are lost in airway epithelium 48 h after infection with H1N1 (MOI = 1056 0.1) (Virus) when treated with 10 µM Nafamostat (Virus + Naf.) (bar, 50 µm)

Production of various influenza-associated cytokines and chemokines in the human

Airway Chip in the presence (+) or absence (-) of 10 µM Nafamostat (Naf.), which 1059 suppresses the cytokine response. (e) Western blots showing inhibition of TMPRSS2-1060 and TMPRSS11D-mediated cleavage of influenza virus HA0 to HA1 by 10 µM

Western blot analysis of SARS-CoV-2 S protein in the lysate of the 1065 HEK293T packaging cell line and in pseudotyped virions in the supernatant showing 1066 that both uncleaved full-length (S1+S2; ~180 kDa) and cleaved forms (~90 kDa) of the 1067 spike protein are present in the virions. A recombinant protein containing the receptor 1068 binding region domain from S1 (RBD fragment) was used as a positive control

Extended Data Fig. 6. Evaluation of the cytotoxicity of test drugs in Huh-7 1075 cells and human Airway chips. (a) Huh-7 cells were treated with the test drugs at 1 or 1076 5 µM for 48 h, and cell viability was measured by Celltiter-Glo assay. The cell viability of 1077 untreated cells was set as 100%. (b) Human Airway Chips were treated with the test 1078 drugs at their respective Cmax for 72 h, cell damage was measure by LDH assay. The 1079 LDH level of untreated human Airway Chips was set as 100%. Note that none of the 1080 drugs produced any significant cytotoxicity at the doses used in these studies

Airway Chips. (a) SARS-CoV-2 spike protein-mediated infection of CoV-2pp in human

Cells were collected for detection of viral gene by RT-1086 qPCR. Data are expressed as fold change in viral gene expression relative to control 1087 pseudoparticles without SARS-CoV-2 spike protein. (b) The infection of SARS-CoV-2pp 1088 was blocked by neutralizing antibody targeting the RBD of spike protein. SARS-CoV-1089 2pp or VSVpp were incubated with neutralizing antibody for 1 h at room temperature 1090 before infecting human airway epithelium. 48 h later, cells were collected for detection 1091 of viral gene by RT-qPCR. PBS was used as control (Ctrl). (c) Immunofluorescence 1092 micrographs showing specific infection of SARS

Extended Data Fig. 8. Effects of desethylamodiaquine on pseudotyped SARS

µΜ), and one day 1099 later chips were infected with SARS-CoV-2pp while in the continued presence of the 1100 drugs for 2 days. The epithelium from the chips were collected for detection of viral 1101 gene by qRT-PCR; viral entry in untreated chips was set as 100%. Extended Data Fig. 9. PK profiles for amodiaquine and desethylamodiaquine in 1104 hamsters. (a) Plasma concentration-time profiles showing mean concentration (± s.d.) 1105 of amodiaquine (left) and desethylamodiaquine (right) at different time points after a 1106 single subcutaneous injection of amodiaquine (50 mg/kg). (b) PK parameters for 1107 amodiaquine and

Concentration of amodiaquine and desethylamodiaquine in tissues (lung, kidney, 1109 intestine, heart) and plasma 24 hours after subcutaneous dosing of 50 mg/kg 1110 amodiaquine

Zhu 1 , Kambez H. Benam 1,+ , Girija Goyal 1

Vascular Biology Program and Department of Surgery, Boston Children's Hospital and Harvard 16 Medical School

Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai

We thank the CDC, Dr. A. Garcia-Sastre, Dr. R.A.M. 765Fouchier, and Dr. X. Sealens for providing the influenza virus strains and the influenza